AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28271251 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in dual therapy stage
Number of subjects: 5535
Study 28271251 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events in triple therapy stage
Number of subjects: 5535
Study 25661661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment
Number of subjects: 1024
Study 25661661 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1024
Study 23822603 — intervention group
Group type: EXPERIMENTAL
Intervention: GLASSIA (alpha1-proteinase inhibitor (human), intravenous)
Number of subjects: 0
Study 23822603 — intervention group
Group type: COMPARATOR
Intervention: PROLASTIN (alpha1-proteinase inhibitor (human), intravenous)
Number of subjects: 0
Study 20658527 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemical fecal occult blood test (FIT)
Number of subjects: 12537
Study 20658527 — intervention group
Group type: COMPARATOR
Intervention: Guaiac fecal occult blood test (G‐FOBT)
Number of subjects: 12537
Study 19249198 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg/day for 6 weeks
Number of subjects: 75
Study 19249198 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 75
Study 16409424 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine 100 microg/day for 6 months
Number of subjects: 60
Study 16409424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15221407 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical heat treatment
Number of subjects: 32
Study 15221407 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching treatment
Number of subjects: 32
Study 15221407 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat plus static stretching treatment
Number of subjects: 32
Study 15221407 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study 11484753 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser angioplasty
Number of subjects: 0
Study 11484753 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study 9405910 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 tablet
Number of subjects: 10
Study 9405910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8432269 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.23 mg kg‐1
Number of subjects: 30
Study 8432269 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 followed by atracurium 0.23 mg kg‐1
Number of subjects: 30
Study 8432269 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium 1 mg kg‐1 and atracurium 0.23 mg kg‐1 in rapid succession
Number of subjects: 30
Study 3322467 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 38
Study 3322467 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 38
Study 31526218 — intervention group
Group type: COMPARATOR
Intervention: Heat-stable rotavirus vaccine (HSRV)
Number of subjects: 100
Study 31526218 — intervention group
Group type: COMPARATOR
Intervention: Comparator (RotaTeq®)
Number of subjects: 100
Study 29181816 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 25
Study 27537264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus intravitreal dexamethasone implant (IVC)
Number of subjects: 40
Study 27537264 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (IVM)
Number of subjects: 40
Study 27537264 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 27537264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (IVM and IVC)
Number of subjects: 40
Study 24846035 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 39 to 234 mg every month
Number of subjects: 311
Study 24846035 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol decanoate 25 to 200 mg every month
Number of subjects: 311
Study 24846035 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 311
Study 24846035 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol decanoate
Number of subjects: 311
Study 21918522 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1-4 mg) at bedtime
Number of subjects: 605
Study 21918522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no add-on medication)
Number of subjects: 605
Study 21918522 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 605
Study 21907255 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanchol vaccine
Number of subjects: 3
Study 18830810 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGASE education program (six hospital-based educational sessions: four collective and two individual)
Number of subjects: 640
Study 18830810 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGASE education program
Number of subjects: 640
Study 18830810 — intervention group
Group type: COMPARATOR
Intervention: Non-trained group (no educational sessions)
Number of subjects: 640
Study 16609067 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP therapy (n = 113)
Number of subjects: 198
Study 16609067 — intervention group
Group type: COMPARATOR
Intervention: CHOP therapy (n = 85)
Number of subjects: 198
Study 16609067 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP and CHOP therapy
Number of subjects: 198
Study 14674501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (no‐etch technique)
Number of subjects: 24
Study 14674501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (no‐etch technique)
Number of subjects: 24
Study 14674501 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single Component
Number of subjects: 24
Study 14674501 — intervention group
Group type: EXPERIMENTAL
Intervention: F2000
Number of subjects: 24
Study 14674501 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 24
Study 14674501 — intervention group
Group type: EXPERIMENTAL
Intervention: NRC/Prime and Bond NT
Number of subjects: 24
Study 14674501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 24
Study 14674501 — intervention group
Group type: COMPARATOR
Intervention: Single Bond (control group)
Number of subjects: 24
Study 10962411 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion of shed mediastinal blood
Number of subjects: 198
Study 10962411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no autotransfusion)
Number of subjects: 198
Study 10962411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 198
Study 8641510 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a) treatment
Number of subjects: 0
Study 8641510 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of GnRH‐a treatment
Number of subjects: 0
Study 8641510 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a treatment
Number of subjects: 0
Study 1456555 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15
Study 1456555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6610938 — intervention group
Group type: EXPERIMENTAL
Intervention: Early use of anticoagulants or platelet inhibiting agents for about one year
Number of subjects: 0
Study 6610938 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0
Study 6610938 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than complete revascularization
Number of subjects: 0
Study 6610938 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 0
Study 6610938 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 0
Study 31074821 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative phase 3 RCTs without a phase 2 trial
Number of subjects: 64600
Study 31074821 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative phase 3 RCTs with a phase 2 trial
Number of subjects: 64600
Study 29245201 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 50
Study 26746121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg buspirone
Number of subjects: 166
Study 26746121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg buspirone
Number of subjects: 166
Study 26746121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 24007934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich fluid (Preop(®), 50 kcal/100 ml)
Number of subjects: 23
Study 24007934 — intervention group
Group type: COMPARATOR
Intervention: Tap water flavoured with lemon (control group, 800 ml + 400 ml)
Number of subjects: 23
Study 22089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with branched-chain amino acid (BCAA; Livact; 12 g/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Number of subjects: 0
Study 22089860 — intervention group
Group type: COMPARATOR
Intervention: Single treatment with BCAA
Number of subjects: 0
Study 22089860 — intervention group
Group type: COMPARATOR
Intervention: Single treatment with ACE-I
Number of subjects: 0
Study 22089860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with BCAA and ACE-I
Number of subjects: 0
Study 20629533 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-100480 (1000 mg)
Number of subjects: 19
Study 20629533 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (300 mg)
Number of subjects: 19
Study 18039363 — intervention group
Group type: EXPERIMENTAL
Intervention: TheoRY-inspired MEssage ('TRY-ME')
Number of subjects: 0
Study 18039363 — intervention group
Group type: COMPARATOR
Intervention: Standard message
Number of subjects: 0
Study 18039363 — intervention group
Group type: EXPERIMENTAL
Intervention: Short directive message
Number of subjects: 0
Study 18039363 — intervention group
Group type: EXPERIMENTAL
Intervention: Long insert or no insert
Number of subjects: 0
Study 18039363 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based outsert or standard outsert or no outsert
Number of subjects: 0
Study 14745283 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and clarithromycin 250 mg b.d. (RLC-1 group)
Number of subjects: 100
Study 14745283 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and clarithromycin 500 mg b.d. (RLC-2 group)
Number of subjects: 100
Study 14745283 — intervention group
Group type: COMPARATOR
Intervention: RLC-1 group
Number of subjects: 100
Study 11534303 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU syntocinon in 20 ml 0.9% NaCl saline intraumbilically (group 1)
Number of subjects: 31
Study 11534303 — intervention group
Group type: COMPARATOR
Intervention: 20 ml 0.9% NaCl saline (group 2)
Number of subjects: 31
Study 11534303 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg ergometrine IUV in 20 ml 0.9% NaCl saline (group 3)
Number of subjects: 31
Study 9918445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 0
Study 9918445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8294678 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (encainide, flecainide, or moricizine)
Number of subjects: 0
Study 8294678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 2725884 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 208-243 (5 to 40 mg)
Number of subjects: 6
Study 2725884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 4595485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (80-120 mg daily)
Number of subjects: 100
Study 4595485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restricted régime
Number of subjects: 100
Study 4595485 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100
Study 31977910 — intervention group
Group type: EXPERIMENTAL
Intervention: Video playback application (SPSRS), 10-minute intervention per day for 5 weeks
Number of subjects: 32
Study 31977910 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 32
Study 30120957 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided radiofrequency ablation (EUS-RFA)
Number of subjects: 26
Study 30120957 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided celiac plexus neurolysis (EUS-CPN)
Number of subjects: 26
Study 28060186 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 15
Study 28060186 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 28060186 — intervention group
Group type: COMPARATOR
Intervention: Electroencephalogram spectral power distributions
Number of subjects: 15
Study 24844542 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with goniosynechialysis (phaco-GSL)
Number of subjects: 43
Study 24844542 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification (phaco)
Number of subjects: 43
Study 22886553 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital exercise training
Number of subjects: 20
Study 22886553 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (Control)
Number of subjects: 20
Study 22325227 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus chemotherapy (Nedaplatin 30 mg/m2 IV once weekly for 4 to 5 weeks + Megestrol 160 mg orally daily during radiation)
Number of subjects: 42
Study 22325227 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 42
Study 19544782 — intervention group
Group type: EXPERIMENTAL
Intervention: Online reoptimization (adapt) with 5 mm PTV margin
Number of subjects: 6
Study 19544782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bony-anatomy matching (bone10) with 10 mm PTV margin
Number of subjects: 6
Study 19544782 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tissue matching (soft10) with 10 mm PTV margin
Number of subjects: 6
Study 19544782 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tissue matching (soft5) with 5 mm PTV margin
Number of subjects: 6
Study 19544782 — intervention group
Group type: COMPARATOR
Intervention: Online reoptimization (adapt) vs new plan
Number of subjects: 6
Study 16672046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine-atropine (Dobatro: up to 40 mcg/kg/min i.v. dobutamine with addition of up to 1 mg of atropine)
Number of subjects: 117
Study 16672046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole-atropine (Dipatro: 0.84 mg/kg over 10 min i.v. dipyridamole with addition of up to 1 mg of atropine)
Number of subjects: 117
Study 16672046 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex, Bruce)
Number of subjects: 117
Study 15911161 — intervention group
Group type: COMPARATOR
Intervention: Rectal placebo (RP)
Number of subjects: 26
Study 15911161 — intervention group
Group type: COMPARATOR
Intervention: Rectal lidocaine (RL)
Number of subjects: 26
Study 15911161 — intervention group
Group type: COMPARATOR
Intervention: Natural history (NH)
Number of subjects: 26
Study 15911161 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo effect)
Number of subjects: 26
Study 15911161 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (to test naloxone antagonism of the placebo effect)
Number of subjects: 26
Study 12150499 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-100 mg sildenafil
Number of subjects: 781
Study 12150499 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 781
Study 10458714 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (12-hour administration)
Number of subjects: 225
Study 10458714 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (24-hour administration)
Number of subjects: 225
Study 10458714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 7789047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized inhaled morphine 10 mg
Number of subjects: 12
Study 7789047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized inhaled morphine 25 mg
Number of subjects: 12
Study 7789047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 2.5 mg
Number of subjects: 12
Study 7789047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7789047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 1.0 mg
Number of subjects: 12
Study 2365189 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (n = 112) - predictive model based on clinical features and laboratory values
Number of subjects: 225
Study 2365189 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (n = 113) - cross-validation of predictive model
Number of subjects: 225
Study 330353 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 S‐15 methyl PGE2 methyl ester
Number of subjects: 77
Study 330353 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 R‐15 methyl PGE2 methyl ester
Number of subjects: 77
Study 330353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 30768369 — intervention group
Group type: EXPERIMENTAL
Intervention: napabucasin plus nab-paclitaxel with gemcitabine
Number of subjects: 0
Study 30768369 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel with gemcitabine
Number of subjects: 0
Study 28107198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Number of subjects: 1089
Study 28107198 — intervention group
Group type: COMPARATOR
Intervention: Horse ATG
Number of subjects: 1089
Study 26115618 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum adiponectin (mean 14.3 ± 6.6 μg/ml)
Number of subjects: 60
Study 26115618 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline urine adiponectin:creatinine (Uadp/cr) (mean 126.8 ± 178.9 μg/ml)
Number of subjects: 60
Study 26115618 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria, hypoalbuminemia, and hyperlipidemia
Number of subjects: 60
Study 23639045 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lenalidomide
Number of subjects: 0
Study 23639045 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg lenalidomide
Number of subjects: 0
Study 23639045 — intervention group
Group type: COMPARATOR
Intervention: 400 mg moxifloxacin (positive control)
Number of subjects: 0
Study 23639045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21877670 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week worksite physical activity intervention
Number of subjects: 58
Study 21877670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 19803566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 102
Study 19803566 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 102
Study 18022084 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist device therapy
Number of subjects: 0
Study 18022084 — intervention group
Group type: COMPARATOR
Intervention: Heart failure
Number of subjects: 0
Study 14743912 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DAC MR axonography
Number of subjects: 20
Study 11561270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal mixture containing bupivacaine 0.125% and sufentanil 0.75 microg/mL with epinephrine 1.25 microg/mL
Number of subjects: 45
Study 11561270 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal mixture containing bupivacaine 0.125% and sufentanil 0.75 microg/mL without epinephrine
Number of subjects: 45
Study 9541845 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vascular surgery (PVS)
Number of subjects: 590
Study 8146894 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (250 micrograms/m2 x 21 days)
Number of subjects: 16
Study 8146894 — intervention group
Group type: COMPARATOR
Intervention: Control (no GM‐CSF)
Number of subjects: 16
Study 3409630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (40 g) plus fat (70 g)
Number of subjects: 9
Study 3409630 — intervention group
Group type: COMPARATOR
Intervention: Fat only
Number of subjects: 9
Study 30989377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes group (HbA1c between 5.7 and 6.4%)
Number of subjects: 4459
Study 30989377 — intervention group
Group type: COMPARATOR
Intervention: Non-prediabetes group
Number of subjects: 4459
Study 30989377 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population analysis
Number of subjects: 4459
Study 28480078 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based only (WO)
Number of subjects: 301
Study 28480078 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based supplemented by peer-led discussion (WD)
Number of subjects: 301
Study 28480078 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based supplemented by professional email counseling (WE)
Number of subjects: 301
Study 28480078 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 301
Study 25609219 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose)
Number of subjects: 4
Study 25609219 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with dronedarone (moderate CYP3A4 inhibitor)
Number of subjects: 4
Study 25609219 — intervention group
Group type: COMPARATOR
Intervention: Predicted AUC0-24 from PBPK model
Number of subjects: 4
Study 22642341 — intervention group
Group type: EXPERIMENTAL
Intervention: Kind Acts
Number of subjects: 142
Study 22642341 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Experiments
Number of subjects: 142
Study 22642341 — intervention group
Group type: COMPARATOR
Intervention: Activity Monitoring
Number of subjects: 142
Study 21460029 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity-encoded (VE) MR imaging
Number of subjects: 33
Study 21460029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging
Number of subjects: 33
Study 21460029 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 33
Study 18299653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg (Group L2)
Number of subjects: 120